Akeso, Summit Drug Extends Survival in Closely Watched Lung Cancer Trial

Lung cancer patients on drug from China’s Akeso lived longer

A lung cancer drug from China's Akeso, ivonescimab, extended patients' lives by about four months in a late-stage trial. Read more at straitstimes.com.

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."

Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial - Regional Media News

By Mariam Sunny and Kamal Choudhury May 31 (Reuters) - An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk of death by more than one-third in a study presented at a medical meeting on Sunday. Patients who received ivonescimab and chemotherapy lived an average of 27.9 months, compared with 23.7 months fo…

New drug combo keeps more lung cancer patients alive at 2 years

Phase III HARMONi-6 found ivonescimab plus chemotherapy cut death risk 34% vs tislelizumab and extended OS to 27.89 vs 23.69 months for patients.

Summit, Akeso drug reduces death by 34% in China lung cancer study. Here’s what it means

CHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus chemotherapy. The results, released in a ...